BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

870 related articles for article (PubMed ID: 18324695)

  • 1. Outcome after percutaneous closure of a patent foramen ovale using the Intrasept device: a multi-centre study.
    Luermans JG; Post MC; Schräder R; Sluysmans T; Vydt T; Vermeersch P; Chessa M; Onorato E; Goy JJ; Budts WI
    Catheter Cardiovasc Interv; 2008 May; 71(6):822-8. PubMed ID: 18324695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patent foramen ovale closure with the Intrasept occluder: Complete 6-56 months follow-up of 247 patients after presumed paradoxical embolism.
    Spies C; Timmermanns I; Reissmann U; van Essen J; Schräder R
    Catheter Cardiovasc Interv; 2008 Feb; 71(3):390-5. PubMed ID: 18288745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Another addition to the tool box.
    Tuzcu EM
    Catheter Cardiovasc Interv; 2008 May; 71(6):829-30. PubMed ID: 18412080
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term results after fluoroscopy-guided closure of patent foramen ovale for secondary prevention of paradoxical embolism.
    Wahl A; Kunz M; Moschovitis A; Nageh T; Schwerzmann M; Seiler C; Mattle HP; Windecker S; Meier B
    Heart; 2008 Mar; 94(3):336-41. PubMed ID: 17639093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous closure of patent foramen ovale in patients with presumed paradoxical embolism: periprocedural results and midterm risk of recurrent neurologic events.
    Balbi M; Casalino L; Gnecco G; Bezante GP; Pongiglione G; Marasini M; Del Sette M; Barsotti A
    Am Heart J; 2008 Aug; 156(2):356-60. PubMed ID: 18657668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Causes of recurrent focal neurologic events after transcatheter closure of patent foramen ovale with the CardioSEAL septal occluder.
    Kutty S; Brown K; Asnes JD; Rhodes JF; Latson LA
    Am J Cardiol; 2008 May; 101(10):1487-92. PubMed ID: 18471463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent events after percutaneous closure of patent foramen ovale.
    Wallenborn J; Bertog SC; Franke J; Steinberg DH; Majunke N; Wilson N; Wunderlich N; Sievert H
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):541-6. PubMed ID: 22707325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism.
    Wahl A; Jüni P; Mono ML; Kalesan B; Praz F; Geister L; Räber L; Nedeltchev K; Mattle HP; Windecker S; Meier B
    Circulation; 2012 Feb; 125(6):803-12. PubMed ID: 22238228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcatheter patent foramen ovale closure for secondary prevention of paradoxical embolic events: acute results from the FORECAST registry.
    Alameddine F; Block PC
    Catheter Cardiovasc Interv; 2004 Aug; 62(4):512-6. PubMed ID: 15274163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of transcatheter patent foramen ovale closure in patients with paradoxical embolism.
    Cifarelli A; Musto C; Parma A; Pandolfi C; Pucci E; Fiorilli R; De Felice F; Nazzaro MS; Violini R
    Int J Cardiol; 2010 Jun; 141(3):304-10. PubMed ID: 19178959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical embolism through the patent foramen ovale--the elderly is where the money is.
    Meier B
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):971-2. PubMed ID: 19021283
    [No Abstract]   [Full Text] [Related]  

  • 13. Transcatheter closure of patent foramen ovale associated with paradoxical embolism using the amplatzer PFO occluder: initial and intermediate-term results of the U.S. multicenter clinical trial.
    Hong TE; Thaler D; Brorson J; Heitschmidt M; Hijazi ZM;
    Catheter Cardiovasc Interv; 2003 Dec; 60(4):524-8. PubMed ID: 14624434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent events following patent foramen ovale closure in patients above 55 years of age with presumed paradoxical embolism.
    Spies C; Khandelwal A; Timmemanns I; Kavinsky CJ; Schräder R; Hijazi ZM
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):966-70. PubMed ID: 18942060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism.
    Chatterjee T; Petzsch M; Ince H; Rehders TC; Körber T; Weber F; Schneider H; Auf der Maur C; Nienaber CA
    J Interv Cardiol; 2005 Jun; 18(3):173-9. PubMed ID: 15966921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes after transcatheter closure of patent foramen ovale in patients with paradoxical embolism.
    Harms V; Reisman M; Fuller CJ; Spencer MP; Olsen JV; Krabill KA; Gray WA; Jesurum JT
    Am J Cardiol; 2007 May; 99(9):1312-5. PubMed ID: 17478164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
    Taggart NW; Reeder GS; Lennon RJ; Slusser JP; Freund MA; Cabalka AK; Cetta F; Hagler DJ
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):124-133. PubMed ID: 27027873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percutaneous closure of patent foramen ovale with a bioabsorbable occluder device: single-centre experience.
    Ussia GP; Cammalleri V; Mulè M; Scarabelli M; Barbanti M; Scardaci F; Mangiafico S; Immè S; Capodanno D; Tamburino C
    Catheter Cardiovasc Interv; 2009 Oct; 74(4):607-14. PubMed ID: 19360875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exclusion of patients with arteriosclerosis reduces long-term recurrence rate of presumed arterial embolism after PFO closure.
    Dubiel M; Bruch L; Liebner M; Schmehl I; Winkelmann A; Rux S; Sonntag S; Wulff H; Grad MO; Kleber FX
    J Interv Cardiol; 2007 Aug; 20(4):275-81. PubMed ID: 17680857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke.
    Thanopoulos BV; Dardas PD; Karanasios E; Mezilis N
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):741-6. PubMed ID: 17039525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.